Eight companies with immunotherapy approaches for brain tumors
2011 Review and Outlook for Biotechnology in 2012
January 25, 2012 By Leave a Comment
Our favorable outlook for the biotechnology industry remains intact for 2012 and is based on several key drivers
2012 Preview: Cancer Immunotherapy Catalysts
December 14, 2011 By 1 Comment
2012 represents a period with robust news flow for emerging immuno-oncology companies
Ipilimumab Approval Highlights Immunotherapy Renaissance
March 25, 2011 By Leave a Comment
On March 25, 2011, Yervoy® [ipilimumab] by Bristol-Myers Squibb became the eleventh mAb approved by the FDA for the treatment of cancer.
To Partner, or Not to Partner: That is the Question
March 10, 2011 By 3 Comments
Traditional wisdom holds that biotechnology companies benefit from collaborations with their larger pharmaceutical peers, which can help validate a company’s technology, provide capital to help fund clinical development, and enable access to experienced clinical, regulatory and commercial infrastructure. While this was certainly true in the early days of biotechnology, the industry has now matured – [...]
Follow MD Becker Partners